Mode
Text Size
Log in / Sign up
N/A N=77 Randomized Treatment

Internet Based Cognitive Behavioral Therapy Effects on Depressive Cognitions and Brain Function

Major Depressive Disorder

Enrolled (actual)
77
Serious AEs
0.0%
Results posted
Dec 2020
Primary outcome: Primary: Change From Pre-treatment to Post-treatment (10 Weeks), Measured by the Hamilton Rating Scale for Depression, 17 Item Version (HRSD-17). — 15.73; 15.70; 9.17; 14.05 score on a scale — p=<0.0001

Study Design & Population

Study type
Interventional
Phase
N/A
Interventions
Internet Cognitive Behavioral Therapy (Behavioral)
Age
Adult · 18+ yrs
Sex
All
Sponsor
Mclean Hospital
Primary completion
Aug 2015

Outcome Measures

OutcomeResultp-value
PRIMARY
Change From Pre-treatment to Post-treatment (10 Weeks), Measured by the Hamilton Rating Scale for Depression, 17 Item Version (HRSD-17).
15.73; 15.70; 9.17; 14.05 <0.0001 sig
SECONDARY
Weekly Patient Health Questionnaire (PHQ-9) Score
9.17; 14.05 .024 sig
SECONDARY
Weekly Kessler Psychological Distress Scale (K-10) Score
20.14; 26.73 .003 sig
SECONDARY
Improvement From Baseline in Brain Functioning on the Emotional Interference Task (EIT) and the Monetary Incentive Delay Task (MID)
SECONDARY
Change From Baseline in Positive and Negative Affect Scale (PANAS) Score
SECONDARY
Change From Baseline in Connor Davidson Resilience Scale (CD-RISC) Score
SECONDARY
Change From Baseline in Modified Erikson Flanker Test
SECONDARY
Change From Baseline in Implicit Association Test (IAT)

Summary

The purpose of this study is to understand the effectiveness of a ten-week internet-based cognitive behavioral therapy (iCBT) treatment on improving depressive symptoms, coping and resilience skills, and cognitive processing.

Eligibility Criteria

Inclusion criteria

  • Age range between 18 and 45.
  • Subjects must be right handed (as measured by Edinburgh Handedness Inventory).
  • The primary language of the subjects must be English
  • Must have regular access to a computer with internet connection and printer (for potential MDD or MAC participants)
  • DSM-IV criteria for current Major Depressive Episode according to SCID (for enrollment into MDD or MAC groups)
  • Absence of any psychotropic medications for at least 2 weeks (6 weeks for fluoxetine; 6 months for neuroleptics; 2 weeks for benzodiazepines; 2 weeks for any other antidepressants)
  • PHQ-9 score below 5 (for enrollment into HC group)

Exclusion criteria

  • Any history of neurological illness or brain injury
  • Current or past DSM-IV Axis I disorder (for enrollment into HC group)
  • Complicating medical conditions that may influence the outcome of neuropsychological assessment or functional imaging (e.g., HIV)
  • Mixed or left-handedness
  • Abnormal visual acuity that is not corrected by contact lenses
  • Metal within the body, claustrophobia, or other contraindications for MRI
  • Less than 9th grade education
  • Past or current alcohol/substance dependence, or current alcohol abuse, or current or past substance abuse (i.e. past alcohol abuse is not exclusionary)
  • Use of illicit drugs within the past year
  • Use of marijuana within the past month
  • Current use of opioid or prescribed stimulant medications
  • History of a psychotic mental illness (schizophrenia or bipolar disorder)
  • Current severe symptoms of depression (total score > 23 or responding > 1 to Question 9 for suicidal ideation in the Patient Health Questionnaire-9 Item [PHQ-9] (Kroenke et al., 2001))
  • A PHQ-9 score below 10 (for potential MDD or MAC participants)
  • Currently participating in Cognitive Behavior Therapy
  • History of ECT treatment
View full record on ClinicalTrials.gov →

Data sourced from ClinicalTrials.gov (NCT01598922). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication.

Back to search